Catalyst Pharmaceuticals Coverage Initiated by Analysts at Stephens
| IMUCDelisted Stock | USD 0.47 0.00 0.00% |
About 56% of ImmunoCellular Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading ImmunoCellular Therapeutics pink sheet suggests that many investors are alarmed at this time. The current market sentiment, together with ImmunoCellular Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use ImmunoCellular Therapeutics stock news signals to limit their universe of possible portfolio assets.
ImmunoCellular |
Stock analysts at Stephens assumed coverage on shares of Catalyst Pharmaceuticals in a note issued to investors on Monday,Briefing.com Automated Import reports. The firm set an overweight rating and a 35.00 price target on the biopharmaceutical companys stock. Stephens price objective suggests a potential upside of 71.32 percent from the stocks
Read at thelincolnianonline.com
 |
ImmunoCellular Therapeutics Fundamental Analysis
We analyze ImmunoCellular Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmunoCellular Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmunoCellular Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
ImmunoCellular Therapeutics is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
ImmunoCellular Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ImmunoCellular Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of ImmunoCellular Therapeutics could also be used in its relative valuation, which is a method of valuing ImmunoCellular Therapeutics by comparing valuation metrics with similar companies.
Peers
ImmunoCellular Therapeutics Related Equities
| PHGUF | Pharming Group | 1.33 | ||||
| LUMO | Lumos Pharma | 0.23 | ||||
| CPRX | Catalyst Pharmaceuticals | 0.19 | ||||
| NWBO | Northwest Biotherapeutics | 3.33 | ||||
| BOLT | Bolt Biotherapeutics | 5.36 | ||||
| CLRB | Cellectar Biosciences | 16.13 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |